New RSV pill for babies shows promise in major trial

NCT ID NCT07402512

First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 11 times

Summary

This study tests an oral medicine called deurremidevir hydrobromide in infants and young children (1 month to 3 years old) with RSV infection. About 498 children will receive either the medicine or a placebo for 5 days. The goal is to see if the medicine helps relieve RSV symptoms like wheezing and fast breathing faster than placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hunan Children's Hospital

    RECRUITING

    Changsha, Hunan, China

    Contact Email: •••••@•••••

  • Shulan(hangzhou)Hospital

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital Of Xiamen University

    RECRUITING

    Xiamen, Fujian, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • West China Second University Hospital Sichuan University

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.